- Home
- MIRM vs ACM Comparison
MIRM vs ACM Comparison
Compare MIRM & ACM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIRM | ACM |
|---|---|---|
| Founded | 2018 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Military/Government/Technical |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 8.5B |
| IPO Year | 2019 | 2007 |
Fundamental Metrics
Financial Performance| Metric | MIRM | ACM |
|---|---|---|
| Price | $91.20 | $62.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 10 |
| Target Price | $119.85 | ★ $131.30 |
| AVG Volume (30 Days) | 464.4K | ★ 1.9M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 1.51% |
| EPS Growth | ★ 74.59 | 42.71 |
| EPS | N/A | ★ 1.29 |
| Revenue | $19,138,000.00 | ★ $16,139,622,000.00 |
| Revenue This Year | $26.22 | N/A |
| Revenue Next Year | $22.04 | $6.06 |
| P/E Ratio | ★ N/A | $48.78 |
| Revenue Growth | N/A | ★ 0.21 |
| 52 Week Low | $63.23 | $60.35 |
| 52 Week High | $130.00 | $135.52 |
Technical Indicators
Market Signals| Indicator | MIRM | ACM |
|---|---|---|
| Relative Strength Index (RSI) | 37.91 | 44.93 |
| Support Level | $88.08 | $60.35 |
| Resistance Level | $98.03 | $71.17 |
| Average True Range (ATR) | 3.90 | 1.74 |
| MACD | -0.37 | -0.05 |
| Stochastic Oscillator | 10.13 | 27.80 |
Price Performance
Historical ComparisonAbout MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
About ACM AECOM
Aecom is one of the largest global providers of advisory, design, and engineering services. It serves a broad spectrum of end markets, including water, transportation, and environment. Based in Dallas, Aecom employs 51,000 people. The company generated $16.1 billion in sales in fiscal 2025.